There are 412 resources available
16P - Determinants of response to short preoperative endocrine therapy (pET) in hormone receptor-positive and HER2-negative (HR+/HER2-) early breast cancer (EBC)
Presenter: Raquel Bravo
Session: Lunch and Poster Display session
17P - Tripartite motif containing 2: S glutamine metabolism-associated protein, predicts poor patient outcome in triple-negative breast cancer treated with chemotherapy
Presenter: Brendah Masisi
Session: Lunch and Poster Display session
18P - Prognostic significance of complete cell cycle arrest in patients with HR+HER2- breast cancer receiving neoadjuvant chemotherapy
Presenter: Sung Gwe Ahn
Session: Lunch and Poster Display session
19P - HER2-low prognosis in early breast cancer: A CANTO based study (LILAC)
Presenter: Lauriane DURAND
Session: Lunch and Poster Display session
20P - Prognostic implications of IGF-1R expression in breast cancer overall and across body mass index groups
Presenter: Signe Borgquist
Session: Lunch and Poster Display session
21P - Tumor cell expressed SDC1 in breast cancer and breast cancer patient survival
Presenter: Song Yao
Session: Lunch and Poster Display session
22P - Unveiling biological and prognostic differences among premenopausal patients with hormone receptor-positive HER2-negative (HR+/HER2-) breast cancer
Presenter: Benjamin Walbaum
Session: Lunch and Poster Display session
23P - Longitudinal evaluation of PAM50 molecular subtypes in patients receiving neoadjuvant HER2-targeted therapy in the PREDIX HER2 trial
Presenter: Emmanouil Sifakis
Session: Lunch and Poster Display session
24P - Letrozole and exemestane as serum estrogen suppressors during neoadjuvant therapy in breast cancer patients: A head-to-head comparison
Presenter: Jürgen Geisler
Session: Lunch and Poster Display session
25P - Immune checkpoint gene expression in breast carcinoma: Correlation with clinicopathological features and prognostic value
Presenter: Yoel Genaro Montoyo-Pujol
Session: Lunch and Poster Display session